EMEA-000410-PIP01-08-M07 - paediatric investigation plan

regadenoson

Key facts

• Invented name:
  Rapiscan
• Active substance:
  regadenoson
• Therapeutic area:
  Cardiac disorders
• Decision number:
  P/0238/2024
• PIP number:
  EMEA-000410-PIP01-08-M07
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Diagnosis of myocardial perfusion disturbances
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  18/07/2024
• Compliance check done:
  Nu

Decision

P/0238/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for regadenoson (Rapiscan), (EMEA-000410-PIP01-08-M07)

Adopted Reference Number: EMA/319202/2024